MSLN and neoplasm: The same mesothelin-targeted engineered T cell receptor is used in TC-510, but it is also engineered with a PD-1/CD28 switch so that PDL-1 expression on the tumor (either baseline or induced by inflammatory cytokines) results in increased activity of the engineered cells rather than inhibition.